Who Owns Enfusion Company?

Who Owns Enfusion?

Enfusion's ownership journey is marked by its recent acquisition by Clearwater Analytics, finalized on April 21, 2025. This strategic move reshapes the landscape for the investment management software provider.

Founded in 1997, Enfusion aimed to revolutionize investment management with a unified, cloud-native SaaS platform. Its comprehensive solutions, including portfolio management and risk management, serve institutional investment managers worldwide.

Who owns Enfusion now?

The acquisition by Clearwater Analytics marks a significant shift in Enfusion's ownership structure. Prior to this, Enfusion's growth was fueled by its innovative platform, which served 916 clients globally as of December 31, 2024. In 2024, the company achieved annual revenue of $201.61 million, reflecting a 15.51% year-over-year increase. Understanding the historical stakes and early investors provides context for its current market standing and strategic direction, especially when considering tools like the Enfusion BCG Matrix.

Enfusion, Inc. was established in 1997 in Chicago, Illinois. Its founding was driven by Tarek Hammoud's vision to enhance investment management software capabilities. Hammoud was later joined by Stephen Malherbe and Scott Werner, who brought valuable development experience from major hedge funds.

Founding Vision

The company's inception was marked by a focus on addressing critical gaps within the investment management software sector. The founders aimed to create a more integrated and efficient technological solution for financial operations.

Early Development

In its formative years, Enfusion largely relied on bootstrapping, emphasizing organic growth fueled by its product offerings. This approach allowed for a strong focus on product development and market fit.

Technological Innovation

A key milestone was the development of the 'Integráta' platform, launched in 2006. This initiative represented a significant step towards building a comprehensive, cloud-native SaaS solution designed for seamless financial technology integration.

Founders' Expertise

The early direction of Enfusion was significantly shaped by the combined expertise of its founders. Their background as developers from large hedge funds provided a deep understanding of industry needs and technological possibilities.

Growth Strategy

The company's early strategy prioritized organic growth, driven by the inherent value and functionality of its software solutions. This allowed for a controlled expansion and a strong foundation in the market.

Founding Team

Tarek Hammoud, Stephen Malherbe, and Scott Werner were the initial driving forces behind Enfusion. Their collective vision was instrumental in shaping the company's technological roadmap and market approach.

While specific equity distributions at the company's inception are not publicly disclosed, the founders' commitment was evident in their dedication to creating a unified, real-time platform. Tarek Hammoud, a key founder, retired and concluded his tenure on Enfusion's Board of Directors in March 2022, marking a significant transition in the company's leadership history. Understanding the Target Market of Enfusion provides context for the company's early strategic decisions and its ongoing development.

Enfusion's journey from a public entity to a subsidiary involved significant shifts in its ownership structure, notably its initial public offering in October 2021 and its subsequent acquisition in April 2025. These events reshaped who owns Enfusion and its position within the financial technology landscape.

Enfusion's public debut on October 21, 2021, saw it list on the New York Stock Exchange under the ticker symbol 'ENFN' with an initial offering price of $17.00 per share. This IPO, which included shares from both Enfusion and existing stockholders, successfully raised $318.75 million. The company employed an 'Up-C' structure, enabling pre-IPO unitholders to retain pass-through tax benefits. Following the IPO, principal stockholders held approximately 83.4% of the combined voting power of Class A and Class B common stock, highlighting concentrated initial ownership.

Key Enfusion Stakeholders and Ownership Dynamics

As of late 2024, significant investment firms were major Enfusion stakeholders. FTV Capital and Malherbe held substantial stakes, influencing the company's direction.

• FTV Capital: Owned 35.7% of Enfusion's common stock.
• Malherbe: Owned 26.5% of Enfusion's common stock.
• Potential Takeover Interest: In 2023, private equity firms including Francisco Partners, Vista Equity Partners, and Irenic Capital Management LP reportedly explored a takeover.
• Market Capitalization (December 31, 2024): Approximately $1.02 billion with 95.6 million shares outstanding.

The landscape of Enfusion ownership underwent a transformative change with its acquisition by Clearwater Analytics, which was finalized on April 21, 2025. This strategic move resulted in Enfusion shareholders having the option to receive either cash or Clearwater Analytics Class A common stock, or a combination of both. Approximately 52% of shares were settled with cash consideration, while the remaining 48% received stock. The acquisition, valued at $1.5 billion, marked Enfusion's transition from a publicly traded company to a component of Clearwater Analytics, effectively establishing Clearwater Analytics as the Enfusion parent company.

Before its acquisition by Clearwater Analytics, Enfusion's board structure reflected its ownership and strategic direction. The board included representatives from key shareholders and independent directors, ensuring a balance of interests.

Enfusion's voting power was managed through a dual-class stock system, comprising Class A and Class B common stock. Each share, regardless of class, granted one vote per share. Notably, holders of Enfusion Ltd. LLC's Common Units possessed all outstanding Class B shares, which, while lacking economic rights, carried significant voting influence. This arrangement ensured that pre-IPO common unitholders maintained substantial control. As of January 7, 2025, specific major stockholders, through formal voting agreements, collectively controlled approximately 45% of Enfusion's total voting power. Enfusion stockholders did not have cumulative voting rights. Following the acquisition by Clearwater Analytics, Enfusion became a subsidiary, and its previous board and voting mechanisms were integrated into Clearwater's corporate governance framework.

Enfusion's Voting Power Dynamics

Enfusion's voting structure was designed to concentrate control with specific stakeholder groups. The Class B shares, held by common unitholders, were key to this structure.

• Two classes of common stock: Class A and Class B.
• Each share entitled the holder to one vote.
• Class B shares were held by common unitholders and carried voting power without economic rights.
• Voting agreements among significant stockholders accounted for 45% of total voting power as of January 7, 2025.
• No cumulative voting rights were available to Enfusion stockholders.

Over the past few years, Enfusion has experienced significant shifts in its ownership landscape. These changes have culminated in its acquisition by Clearwater Analytics, marking a new chapter for the company.

In 2023, Enfusion was reportedly a target for several private equity firms, including Francisco Partners, Vista Equity Partners, and Irenic Capital Management LP. During this period, the company also saw changes in its executive leadership, with new individuals stepping into the CEO and CFO positions. The most impactful development occurred on April 21, 2025, when Clearwater Analytics finalized its acquisition of Enfusion for $1.5 billion. This transaction transitioned Enfusion from a publicly traded entity (NYSE: ENFN) to a subsidiary of Clearwater Analytics. Enfusion shareholders had the choice to receive either cash or Clearwater Analytics stock, with approximately 52% opting for cash and 48% for stock. This move aligns with a broader trend of consolidation within the financial software industry, as companies aim to broaden their service portfolios and market presence. Enfusion's annual revenue for 2024 reached $201.61 million, representing a 15.51% increase from the prior year. However, the first quarter of 2025 reported an Earnings Per Share (EPS) forecast of $0.04, a decrease from the $0.06 reported in the first quarter of 2024, suggesting potential short-term financial adjustments. Discussions surrounding the acquisition highlight anticipated synergies designed to strengthen the combined entity's standing in the investment management technology sector. For a deeper understanding of its past, refer to the Brief History of Enfusion.

Acquisition by Clearwater Analytics

Clearwater Analytics acquired Enfusion for $1.5 billion on April 21, 2025. This made Enfusion a subsidiary of Clearwater Analytics.

Shareholder Consideration

Enfusion shareholders could elect to receive cash or Clearwater Analytics stock. Approximately 52% chose cash, and 48% chose stock.

Financial Performance

Enfusion reported $201.61 million in annual revenue for 2024, a 15.51% increase year-over-year. The Q1 2025 EPS forecast is $0.04, down from $0.06 in Q1 2024.

Industry Consolidation Trend

The acquisition reflects a broader trend of consolidation in the financial software sector. Companies are merging to expand integrated offerings and market reach.